DexCom's SWOT analysis: stock faces challenges amid growth potential
DexCom , Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM) systems for diabetes management with a market capitalization of $34.8 billion, finds itself at a critical juncture as it ...
Leerink Partnrs Issues Positive Outlook for DexCom Earnings
Stock analysts at Leerink Partnrs increased their Q1 2025 earnings per share estimates for DexCom in a research report issued ...
Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom
DexCom reported Q4 revenue of $1.11 billion, surpassing estimates. The company reaffirmed its 2025 outlook while analysts ...
DexCom: Revenue Up, EPS Misses Mark
Looking forward, DexCom's management has reiterated its fiscal year 2025 forecast, anticipating revenue growth of 14% with a ...
DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Kingsview Wealth Management LLC
Kingsview Wealth Management LLC cut its stake in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 45.0% in the 4th quarter, according to the company in its most recent disclosure with the ...
BofA says use DexCom’s stock move as buying opportunity
DexCom (DXCM) shares are down on Monday morning on a notification that some customers are receiving 30 days of supplies instead of 90 days amid ...
Dexcom Q4 Earnings: Expanding Sales, New Products, Margin Pressure And More
Dexcom reported Q4 results, with revenue up 8%, beating estimates. CEO looks forward to unlocking next wave of global access.
AOL4d
Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom
She notes that DexCom is positioned for long-term growth, supported by its expanding product lineup, including G7, Dexcom One, and Stelo, and opportunities to reach new patient groups. However ...